Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$20.75M+3.9%$19.97M+55.0%$12.88M+3.4%$12.46M+42.7%$8.73M-18.7%
$1.32M-29.8%$1.88M+11.9%$1.68M-1.4%$1.7M+56.9%$1.09M-13.9%
$19.43M+7.4%$18.09M+61.5%$11.2M+4.2%$10.75M+40.7%$7.64M-19.3%
93.6%+3.1pp90.6%+3.6pp87%+0.6pp86.3%-1.2pp87.6%-0.7pp
$81.15M-7.8%$88.06M+1.5%$86.8M-5.6%$91.94M+26.4%$72.74M-12.2%
$48.3M-6.4%$51.61M+25.0%$41.27M-10.0%$45.87M+10.5%$41.53M-19.7%
$130.77M-7.6%$141.55M+9.1%$129.75M-7.0%$139.51M+20.9%$115.36M-15.0%
-$110.03M+9.5%-$121.58M-4.0%-$116.87M+8.0%-$127.06M-19.2%-$106.63M+14.7%
-530.3%+78.6pp-608.9%+298pp-907.4%+113pp-1,020.1%+202pp-1,222%-56.7pp
$10.8M-13.0%$12.41M-7.2%$13.37M-7.9%$14.51M-9.8%$16.09M-10.7%
$119K+5.3%$113K+68.7%$67K-87.2%$523K-58.3%$1.25M-22.8%
-$99.11M+8.3%-$108.04M-4.5%-$103.43M+7.7%-$112.02M-25.5%-$89.29M
-477.7%+63.4pp-541.1%+262pp-803.1%+96.3pp-899.4%+124pp-1,023.3%
-$1.69+8.6%-$1.85-3.9%-$1.78+7.8%-$1.93-24.5%-$1.55
-$108.66M+9.7%-$120.31M-4.2%-$115.5M+8.2%-$125.8M-19.4%-$105.35M+14.8%
-523.8%+78.8pp-602.6%+294pp-896.7%+113pp-1,010%+197pp-1,207.3%-54.8pp
-$110.03M+9.5%-$121.58M-4.0%-$116.87M+8.0%-$127.06M-19.2%-$106.63M+14.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Agios Pharmaceuticals's revenue?
Agios Pharmaceuticals (AGIO) generated $66.0M in revenue over the trailing twelve months, up 78.3% year over year.
Is Agios Pharmaceuticals profitable?
Agios Pharmaceuticals is not currently profitable: it reported a net loss of $422.6M over the trailing twelve months, a -639.8% net margin.
What are Agios Pharmaceuticals's profit margins?
Gross margin is 90.0% and operating margin is -720.0%, with a -639.8% net margin.
What is Agios Pharmaceuticals's earnings per share?
Agios Pharmaceuticals's diluted EPS over the trailing twelve months is $-7.25.
Where does Agios Pharmaceuticals's income statement data come from?
Every line is extracted from Agios Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.